Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naim Alkhouri

Showing results (201-210 of 306) with videos related to

Pageof 31
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 22, 2024
Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced FibrosisMazen Noureddin, Michael R Charlton, Stephen A Harrison, et al.
Obesity (Silver Spring, Md.)|January 9, 2026
Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE StudyHarold E Bays, Phillip Toth, Naim Alkhouri, et al.
Hepatology Communications|January 29, 2024
Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction-associated steatohepatitisSven M Francque, Alexander Hodge, Jerome Boursier, et al.
World Journal of Hepatology|November 22, 2019
Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohortGeorge Khoudari, Amandeep Singh, Mazen Noureddin, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 22, 2011
Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver diseaseNaim Alkhouri, Gareth Morris-Stiff, Carla Campbell, et al.
Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation|September 28, 2017
Accuracy of Noninvasive Fibrosis Scores in Predicting the Presence of Fibrosis in Patients after Liver TransplantationMohammad Nasser Kabbany, Praveen Kumar Conjeevaram Selvakumar, John Guirguis, et al.
Journal of Clinical Gastroenterology|March 14, 2020
Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver DiseaseAmandeep Singh, Falgun Gosai, Mohamed T Siddiqui, et al.
Nature Medicine|October 16, 2023
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trialStephen A Harrison, Rebecca Taub, Guy W Neff, et al.
Digestive Diseases and Sciences|December 26, 2014
The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver diseaseSana Mansoor, Lisa Yerian, Rohit Kohli, et al.
Plos One|October 5, 2018
Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosisNaim Alkhouri, Casey Johnson, Leon Adams, et al.
Pageof 31

Showing results (201-210 of 306) with videos related to

Sort By:
Pageof 31
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 22, 2024
Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced FibrosisMazen Noureddin, Michael R Charlton, Stephen A Harrison, et al.
Obesity (Silver Spring, Md.)|January 9, 2026
Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE StudyHarold E Bays, Phillip Toth, Naim Alkhouri, et al.
Hepatology Communications|January 29, 2024
Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction-associated steatohepatitisSven M Francque, Alexander Hodge, Jerome Boursier, et al.
World Journal of Hepatology|November 22, 2019
Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohortGeorge Khoudari, Amandeep Singh, Mazen Noureddin, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 22, 2011
Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver diseaseNaim Alkhouri, Gareth Morris-Stiff, Carla Campbell, et al.
Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation|September 28, 2017
Accuracy of Noninvasive Fibrosis Scores in Predicting the Presence of Fibrosis in Patients after Liver TransplantationMohammad Nasser Kabbany, Praveen Kumar Conjeevaram Selvakumar, John Guirguis, et al.
Journal of Clinical Gastroenterology|March 14, 2020
Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver DiseaseAmandeep Singh, Falgun Gosai, Mohamed T Siddiqui, et al.
Nature Medicine|October 16, 2023
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trialStephen A Harrison, Rebecca Taub, Guy W Neff, et al.
Digestive Diseases and Sciences|December 26, 2014
The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver diseaseSana Mansoor, Lisa Yerian, Rohit Kohli, et al.
Plos One|October 5, 2018
Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosisNaim Alkhouri, Casey Johnson, Leon Adams, et al.
Pageof 31